For laboratory research use only. Not for human or veterinary use. This is educational reference information, not medical advice.
Research Database / Peptides / SLU-PP-332
SLU-PP-322 · SLU-PP-332

SLU-PP-332

Research Series
Overview Research Publications Laboratory FAQ References
Overview
Scientific nameSLU-PP-332
AbbreviationSLU-PP-322
CAS Number303760-60-3
Molecular formulaC18H14N2O2
Molecular weight290.3 g/mol (average)
PubChem CID5338394
2D / 3D structure
2D chemical structure of SLU-PP-332
Research Summary

Mechanisms under investigation

The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.

Evidence tiers below reflect how much has been studied in each model type. Counts describe research volume — they do not indicate proven efficacy, safety, or clinical consensus.

Evidence base (transparent counts)

Cellular studies 2 publications
Animal studies 3 publications
Human observational reports 0 publications
Controlled human trials 0 publications
Review articles 1 publication
Publication Library

Selected literature

Filter by study model. Each record is classified for the evidence base above.

2026
Systematic review summarizing pharmacological activation of ERRα/β/γ as an exercise-mimetic strategy, including reported work on SLU-PP-332.Review · PubMed (42024694)
2026
Medicinal-chemistry study describing structural optimization of SLU-PP-332 analogues and characterization of their estrogen-related receptor signaling activity.Cellular · PubMed (41850449)
2026
In vitro metabolism study identifying SLU-PP-332 metabolites for use as analytical targets in doping-control testing.Cellular · PubMed (41688415)
2024
Preclinical study examining the effects of the synthetic ERR agonist SLU-PP-332 on metabolic parameters in a rodent model of metabolic syndrome.Animal · mouse · PubMed (37739806)
2024
Preclinical study evaluating pan-ERR agonists including SLU-PP-332 on cardiac fatty acid metabolism and mitochondrial function in a mouse pressure-overload heart failure model with supporting cardiomyocyte experiments.Animal · mouse · PubMed (37961903)
2023
Preclinical study reporting that the pan-ERR agonist SLU-PP-332 induced an ERRα-dependent acute aerobic exercise transcriptional response and altered running capacity in mice.Animal · mouse · PubMed (36988910)

Each record maps to a structured evidence row with study model, species, and support level.

Laboratory Information

Handling and reference

Molecular weight calculator

Average-mass estimate from a one-letter sequence.

Reconstitution calculator

Laboratory concentration only. Not dosing guidance.

Frequently Asked Questions
What is SLU-PP-332?
SLU-PP-322 is a small-molecule research compound; the identity and structure data shown here are compiled from public chemical databases (primarily PubChem). For laboratory research use only.
What research models has it been studied in?
The literature indexed here is predominantly cellular (in vitro) and animal studies. See the evidence base and publication library above for the transparent counts by study model.
Is there controlled human clinical trial evidence?
Controlled human clinical trials are counted separately in the evidence base above. Cellular and animal findings do not establish human clinical effects.
How is it stored and handled in a laboratory?
Refer to the laboratory information section above.
Is this intended for human use?
No. All information and materials are for laboratory research use only — not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease.
Documentation

Research material & documentation

This profile is an educational reference. Lot-level laboratory documentation for materials supplied by Peptide Titans is published openly.

SLU-PP-332 research material →  ·  Lot-specific Certificates of Analysis →  ·  How lots are tested →

References and Citation

Evidence records

  1. Systematic review summarizing pharmacological activation of ERRα/β/γ as an exercise-mimetic strategy, including reported work on SLU-PP-332. (2026) — review — PubMed.
  2. Medicinal-chemistry study describing structural optimization of SLU-PP-332 analogues and characterization of their estrogen-related receptor signaling activity. (2026) — in vitro — PubMed.
  3. In vitro metabolism study identifying SLU-PP-332 metabolites for use as analytical targets in doping-control testing. (2026) — in vitro — PubMed.
  4. Preclinical study examining the effects of the synthetic ERR agonist SLU-PP-332 on metabolic parameters in a rodent model of metabolic syndrome. (2024) — in vivo — PubMed.
  5. Preclinical study evaluating pan-ERR agonists including SLU-PP-332 on cardiac fatty acid metabolism and mitochondrial function in a mouse pressure-overload heart failure model with supporting cardiomyocyte experiments. (2024) — in vivo — PubMed.
  6. Preclinical study reporting that the pan-ERR agonist SLU-PP-332 induced an ERRα-dependent acute aerobic exercise transcriptional response and altered running capacity in mice. (2023) — in vivo — PubMed.

Every record carries a study model, species, support level and review status in the evidence table.

Citation generator

Loading citation...

Explore the full research database

Browse peptide profiles, publications, and laboratory references — all research-only.

For laboratory research use only. Not for human or veterinary use. Educational reference information — not medical advice.